BOSTON, MASS., November 4, 2014. AbVitro Inc., a therapeutic target discovery company, announced that Samuel Broder, M.D. has been appointed to its board of directors and scientific advisory board. Dr. Broder, former director of the National Cancer Institute, brings extensive experience in oncology and drug development.
“We are very fortunate to have attracted such an experienced clinician scientist with both academic and industry experience to our board,” said Jeffrey M. Ostrove, Ph.D., AbVitro’s chief executive officer. “Dr. Broder brings a wealth of knowledge in the immuno-oncology and immunologic disease space, supporting many of the areas that our immune sequencing technology is so powerful in.”
“AbVitro’s unique, high-capacity single-cell immune sequencing technology is a brilliant advance. It represents a paradigm shift in identifying novel therapeutic and diagnostic targets, as well as completely human monoclonal antibodies related to cancer, autoimmune and infectious diseases, or any condition that features an immune component,” stated Dr. Broder.
“We are tremendously pleased to welcome Dr. Sam Broder to the board of directors of AbVitro. Having someone of Dr. Broder’s stature on the board not only validates our enthusiasm about the power and potential of this promising technology, but his deep expertise and experience will be invaluable to the company going forward,” noted Casey Cunningham, M.D., a medical oncologist who is a member of AbVitro’s board of directors and the chief scientific officer of Santé Ventures, the lead investor in AbVitro Inc.
Samuel Broder, M.D. is the former director of the National Cancer Institute (NCI), appointed by President Ronald Reagan. In this position, he oversaw the development of a number of new therapies for cancer including paclitaxel (Taxol). He was also a co-developer of some of the first effective drugs for the treatment of AIDS (zidovudine, AZT; didanosine, ddI; and zalcitabine, ddC). After leaving the NCI, Dr. Broder became senior vice president for research and development at IVAX Corporation in Florida, a position he held until 1998 when he joined Celera Genomics as chief medical officer. He has received a number of honors for his work including the Arthur S. Flemming Award and the Leopold Griffuel Award.
AbVitro is a therapeutic target discovery company, with a unique technology platform that leverages natural immune responses to address diseases with unmet medical needs. Based on technology developed by the visionary George Church at Harvard Medical School, AbVitro’s technology allows for the identification of complete, natively paired B cell antibodies and T cell receptors across millions of single cells at unprecedented resolution. This high-throughput single-cell immune sequencing technology is then used to identify novel therapeutic targets and antibodies to cancer, autoimmune and infectious diseases, as well as utility in any disorder that has an immune component. For more information visit http://www.AbVitro.com
About Santé Ventures
Santé Ventures is a life sciences venture capital firm that invests exclusively in early-stage companies developing innovative new medical technologies or healthcare delivery models. The firm was founded in 2006 and has $270 million in capital under management in two funds. For more information, visit www.santeventures.com